Empowering Natural Tissue Regeneration

About Us

Who we are

Osteopore is a global medical technology company founded in Singapore and listed in Australia, commercialising products designed to enable natural bone healing across multiple therapeutic areas. Osteopore's patented technology fabricates specific micro-structured scaffolds for bone regeneration through 3D printing and bioresorbable material.
Osteopore's patent-protected scaffolds are manufactured using a proprietary manufacturing technique with a polymer that naturally dissolves over time to allow natural and healthy bone tissue, significantly reducing the post-surgery complications commonly associated with permanent bone implants. Our 3D printing technology is unique to Osteopore.

Our roots

Our founders, comprising a team of 6 clinicians and scientists, got together in 1996 to reimagine patient healing. They envisioned a future where bone and other tissues are empowered to heal with a technology that supports regeneration. In 2003, Osteopore was established.
Today, Osteopore continues to carry forth their vision for improved patient healing: expanding our global presence, developing cutting-edge technology, identifying new innovations.

Our technology

We are the first company in the world to obtain market authorisation for our 3D printed bone scaffold. Our core technology leverages our collective knowledge and experience on how bone and tissue heals – we continue to learn and adapt with every implant.
We believe in creating a conducive environment for tissue regrowth while minimising long-term impact of biomaterials that remain in the body. We own our technology – Osteopore’s 3D printers are designed to support our mission to Empower Natural Tissue Regeneration.
We continue to innovate by adopting an open innovation mindset – collaborations and joint-developments are part of our DNA.

Our team

Board of Directors

Mark LeongACCA, ISCA, SID
Executive Chairman
Lim YujingPhD
Executive Director
Chief Executive Officer
Chief Technology Officer
Prof. Teoh Swee HinB Eng (Hons I), PhD (Materials Engineering)
Non-Executive Director
Hon. Michael Keenan
Non-Executive Director

Key Team Members

Lim YujingPhD
Executive Director
Chief Executive Officer
Chief Technology Officer
Voon Shu NingCPA
Group Financial Controller
Ammar HassanbhaiPhD
Senior Manager, Quality Assurance
James Lim Jae Hoon
Country Manager, Korea
Global Business Director, Aesthetic Rhinoplasty
Close

Mark Leong

ACCA, ISCA, SID
Executive Chairman

Mr Leong is a Fellow of the Association of Chartered Certified Accountants (ACCA), Chartered Accountant of the Institute of Singapore Chartered Accountants (ISCA) and Member of the Singapore Institute of Directors (SID).

An Australian Permanent Resident, Mr Leong has considerable corporate, management and directorship experience in a broad range of functions and industries having undertaken several C-suite roles (CEO, COO, & CFO) in several private as well as listed companies. Mr Leong presently serves as a Non-Executive & Independent Director in several Singapore and Australian listed companies.

Close

Lim Yujing

PhD
Executive Director
Chief Executive Officer
Chief Technology Officer

Dr. Lim holds a PhD from Nanyang Technological University, Singapore. Prior to joining Osteopore (OSX.AX), Dr. Lim conducted research on biomaterials for tissue engineering and regenerative medicine, and developed material fabrication platforms. He published 14 articles in internationally peer-reviewed journals in that time. Dr. Lim joined Osteopore (OSX.AX) in December 2014, and has led Osteopore (OSX.AX) to important regulatory and quality milestones. In addition, Dr. Lim led the expansion of product and therapy portfolio, and contributed to the improvement in manufacturing efficiency.

Close

Prof. Teoh Swee Hin

B Eng (Hons I), PhD (Materials Engineering)
Non-Executive Director

Prof Teoh Swee Hin, is the President’s Chair, School of Chemical and Biomedical Engineering (SCBE). He holds a joint appointment with the Lee Kong Chian School of Medicine (LKC Med) at Nanyang Technological University. His contribution is in the development and clinical translation of 3D bioresorbable scaffolds. Majoring in Materials Engineering (B. Eng -1st Class Hon and PhD, Monash University), his research journey focused at translating the materials research to biomedical benefits. He is a Fellow of the Academy of Engineers Singapore and Chief Engineer at Skin Research Institute of Singapore. His research focused on the study of mechanisms that promote cells proliferation and differentiation as a result of mechno induction through load bearing scaffolds for tissue regeneration and remodelling.

Prof Teoh’s pioneering work on 3D printed scaffold led to him receiving the prestigious “Golden Innovation Award” at the Far East Economic Review, and the Institute of Engineers “Prestigious Engineering Achievement Award” in 2004. His group was ranked 1st in bone tissue engineering scaffolds in World Web of Science 2010. He was honoured with the Special Award for “Scientific Life-Time Achievement in Bone Tissue Engineering” at Bone-Tec 2015, Stuttgart. As a part of SG50 celebrations, he was featured as one of Singapore’s profiled scientists in the book titled “Singapore’s Scientific Pioneers”.

Professor Teoh is presently the Chairman, Singapore Academy, Asia Regulatory Professional Association (ARPA). He sits on the board of editors for Tissue Engineering, Journal of Tissue Engineering and Regenerative Medicine, Journal of Mechanical Behaviour of Biomedical Materials, Journal of Oral & Maxillofacial Research and Proceedings of the Institution of Mechanical Engineers Part H: Journal of Engineering in Medicine.

Close

Hon. Michael Keenan

Non-Executive Director

A former Australian Government Cabinet Minister, Mr. Keenan served as a Federal Member of Parliament from 2004 to 2019, holding senior ministry positions in the Abbott, Turnbull, and Morrison Governments from 2013 to 2019. His ministerial portfolios included Human Services, where he provided direction and oversight of Medicare, as well as Justice, Counter-Terrorism, and Digital Transformation. Notably, Mr. Keenan also serves on the Board of U Group and Co, as well as the Australian Strategic Policy Institute.

Close

Lim Yujing

PhD
Executive Director
Chief Executive Officer
Chief Technology Officer

Dr. Lim holds a PhD from Nanyang Technological University, Singapore. Prior to joining Osteopore (OSX.AX), Dr. Lim conducted research on biomaterials for tissue engineering and regenerative medicine, and developed material fabrication platforms. He published 14 articles in internationally peer-reviewed journals in that time. Dr. Lim joined Osteopore (OSX.AX) in December 2014, and has led Osteopore (OSX.AX) to important regulatory and quality milestones. In addition, Dr. Lim led the expansion of product and therapy portfolio, and contributed to the improvement in manufacturing efficiency.

Close

Voon Shu Ning

CPA
Group Financial Controller

Ms Voon holds a Bachelor of Accounting First Class Honours and is a member of CPA Australia.

Ms Voon has approximately 10 years of experience in the accounting field, and is currently responsible for all functions relating to finance, accounting and corporate reporting matters in Osteopore. Prior to joining Osteopore, Ms Voon worked in a SGX listed company, and previously was an audit supervisor in an audit firm.

Close

Ammar Hassanbhai

PhD
Senior Manager, Quality Assurance

Dr Ammar Hassanbhai is Senior Manager of Quality Assurance at Osteopore, where he ensures product quality and safety across the entire lifecycle of Osteopore’s bioresorbable implants. He holds a PhD in Microbiology from the National University of Singapore (NUS) and completed postdoctoral research in tissue engineering, focusing on vascular decellularisation, bacterial cancer therapies, and antimicrobial films.

With a strong background in both science and quality systems, Dr Ammar plays a key role in maintaining Osteopore’s commitment to innovation and world-class healthcare outcomes.

Close

James Lim Jae Hoon

Country Manager, Korea
Global Business Director, Aesthetic Rhinoplasty

Mr Lim Jae Hoon is a highly experienced professional with an enviable track record of over 30 years’ business experience in medical device sales and marketing, with increasing responsibilities from sale representative to Country Manager and Regional Manager. A large portion of that time was with Johnson & Johnson Orthopaedic division (12 years), followed by Edwards Lifesciences (9 years).​

As a distributor for Osteopore, he was instrumental in the Company entering the rhinoplasty market in Asia, which has grown to become a significant revenue driver for the Company. He also co-developed a number of Osteopore products for this market, and has built a growing network of surgeons in the region​

Close

About Us

Are you a Healthcare Professional?

The content of the Healthcare Professional pages is intended for a medical specialist audience only.
By using this site or downloading materials from the site, you agree to abide by the terms and conditions set forth in our Privacy Policy and Legal Notice.

No, I am not a Healthcare professional. Please take me to the Patient Care content, or the Homepage.